Crystals of indole-hepta-membered oxime analogs used as PARP inhibitors and methods for preparing the same
By developing a crystallization of an indole septaxime analog, the problem of poor effect of existing PARP inhibitors was solved, effective inhibition of PARP1 enzyme and anti-proliferative effects of BRCA1 mutant cells were achieved, and the drug substitution was performed Kinetic stability and high bioavailability.
Patent Information
- Application Number
- CN202180041399.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-08-04
- Filing Date
- 2021-07-30
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2041-07-30
AI Technical Summary
Existing PARP inhibitors are not satisfactory in the treatment of cancer and other diseases, and no satisfactory treatment options have been developed, and new PARP inhibitors are urgently needed.
Develop a crystal of an indole septaxime analog, prepared by methods such as X-ray powder diffraction spectral characteristic peaks and differential scanning calorimetry curves of Cu Kα radiation, and used to prepare pharmaceutical compositions for the treatment of PARP receptor-related disease.
This compound has strong inhibitory activity on PARP1 enzyme, shows excellent selectivity and safety, has anti-proliferative activity against BRCA1 mutant cells, and shows stability and high bioavailability in pharmacokinetic properties.
Smart Images

Figure CN115698019B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the rights and priority of Chinese invention patent application No. 202010762484.9 filed with the State Intellectual Property Office of the People's Republic of China on July 31, 2020, and Chinese invention patent application No. 202010772764.8 filed with the State Intellectual Property Office of the People's Republic of China on August 4, 2020, the entire contents of which are hereby incorporated by reference into this document in their entirety. Technical Field
[0003] The present application relates to the crystallization of an indole-heptacyclic oxime analogue used as a PARP inhibitor and a method for preparing the same, and specifically to the crystallization of a compound represented by formula (I) and a method for preparing the same. Background Art
[0004] PARP (ploy (ADP-ribose) polymerase) is a type of poly ADP-ribose polymerase, which is a family of enzymes that can be used to catalyze the addition of ADP-ribose residues to various target proteins. To date, a total of 18 subtypes have been identified and characterized. Although there are many types of enzymes in the PARP family, PARP-1 is responsible for more than 90% of ADP-ribosylation in cells, so research on PARP inhibitors has mainly focused on PARP-1 inhibitors.
[0005] In the human living environment, human DNA is always damaged by the natural environment (such as oxidative stress, radiotherapy and chemotherapy, etc.). PARP-1 is closely related to DNA repair and genome function maintenance. When DNA is damaged, it is generally a single strand break (SSB). PARP-1 first binds to the break of DNA and then is activated. As the structure of the PARP1 enzyme changes, the enzyme begins to recruit NAD+ (coenzyme II) to synthesize poly (ADP) ribose. At the same time, this also becomes a signal for other repair enzymes such as DNA ligase and DNA polymerase β to play a role. This process of PARP-1 binding and activation is called base excision repair (BER), which helps the DNA amplification repair process. When PARP-1 is inhibited by PARP inhibitors, DNA cannot repair broken DNA through SSB, which activates double strand breaks (DSB). The body repairs DSB mainly in two ways: homologous recombination (HR) and non-homologous DNA end joining (NHEJ). Homologous recombination is the main way to repair DSB, and the repair reliability is high. BRCA1 and BRCA2 play an important role in homologous recombination (Nature, 2005, 913-917). Studies have found that BRCA1 / 2 mutations are found in ovarian cancer, breast cancer, and prostate cancer. PARP inhibitors are a good choice for tumors lacking BRCA1 / 2. In addition to being used alone, PARP inhibitors can also be used in combination with chemotherapy drugs and radiotherapy drugs to achieve the purpose of reducing dosage and improving efficacy. Based on this, people have developed a series of different types of compounds (J.Med.Chem.2010,4561), among which Olaparib, Rucaparib, Niraparib (MK-4827), and Talazoparib (BMN-673) have been successfully marketed. Nevertheless, as the indications of PARP inhibitors continue to expand, the application of PARP inhibitors is also constantly deepening, not only around tumors, but also has certain effects on stroke, myocardial ischemia, inflammation and diabetes. There are still many clinical trials underway.
[0006]
[0007] Although efforts to develop PARP inhibitors for the treatment of cancer and other diseases have been ongoing, satisfactory treatments have not been achieved, and thus there remains an urgent need to develop new PARP inhibitors. SUMMARY OF THE INVENTION
[0009] In one aspect, the present application provides a compound of formula (I),
[0010]
[0011] In another aspect, the present application provides a crystal of the compound of formula (I).
[0012] On the other hand, the present application provides a crystalline composition of a compound of formula (I), wherein the crystals of the compound of formula (I) account for more than 50% by weight of the crystalline composition, preferably more than 75%, more preferably more than 90%, and most preferably more than 95%.
[0013] On the other hand, the present application provides a pharmaceutical composition, which comprises a therapeutically effective amount of the compound of formula (I) above, or its crystal, or a crystalline composition of the compound of formula (I) above; the pharmaceutical composition may comprise at least one pharmaceutically acceptable carrier or other excipient.
[0014] On the other hand, the present application provides the use of the compound of formula (I), the crystal of the compound of formula (I), the crystalline composition of the compound of formula (I), or the pharmaceutical composition in the preparation of a drug for preventing or treating PARP receptor-related diseases.
[0015] On the other hand, the present application provides the use of the compound of formula (I), the crystal of the compound of formula (I), the crystalline composition of the compound of formula (I), or the pharmaceutical composition for preventing or treating PARP receptor-related diseases.
[0016] On the other hand, the present application provides a method for preventing or treating PARP receptor-related disorders, which comprises administering to a mammal in need thereof a therapeutically effective amount of the compound of formula (I), a crystal of the compound of formula (I), a crystalline composition of the compound of formula (I), or the pharmaceutical composition.
[0017] In another aspect, the present application provides the compound of formula (I) above, a crystal of the compound of formula (I), a crystalline composition of the compound of formula (I) above, or the pharmaceutical composition above, which is used as a PARP inhibitor.
[0018] On the other hand, the present application provides the compound of formula (I), the crystal of the compound of formula (I), the crystalline composition of the compound of formula (I), or the pharmaceutical composition for preventing or treating PARP receptor-related disorders.
[0019] On the other hand, the present application provides a method for preparing a compound of formula (I) or a crystal thereof, wherein the method for preparing the crystal is: heating and stirring an amorphous substance of the compound of formula (I) in an organic solvent, further cooling and crystallizing, and filtering to prepare the crystal; the amorphous substance of the compound of formula (I) has an X-ray powder diffraction spectrum using Cu Kα radiation such as Figure 1 As shown; in the preparation method of the crystal, the organic solvent is selected from acetone, tetrahydrofuran and ethyl acetate; preferably acetone. Summary of the invention
[0020] In one aspect, the present application provides a compound of formula (I),
[0021]
[0022] On the other hand, the present application also provides a crystal of the compound of formula (I).
[0023] In one embodiment of the present application, the crystalline A of the compound of formula (I), its X-ray powder diffraction spectrum using Cu Kα radiation comprises 2, 3 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 8.59±0.20°, 16.00±0.20°, 20.76±0.20°, 25.14±0.20° and 25.96±0.20°.
[0024] In one embodiment of the present application, the crystalline A of the compound of formula (I), its X-ray powder diffraction spectrum using Cu Kα radiation comprises 3, 4, 5, 6 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 8.59±0.20°, 11.74±0.20°, 12.34±0.20°, 16.00±0.20°, 20.76±0.20°, 25.14±0.20° and 25.96±0.20°.
[0025] In one embodiment of the present application, the crystalline A of the compound of formula (I), its X-ray powder diffraction spectrum using Cu Kα radiation comprises 3, 4, 5, 6 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 8.59±0.20°, 11.74±0.20°, 12.56±0.20°, 16.00±0.20°, 20.76±0.20°, 25.14±0.20° and 25.96±0.20°.
[0026] In one embodiment of the present application, the crystalline A of the compound of formula (I), its X-ray powder diffraction spectrum using Cu Kα radiation comprises 3, 4, 5, 6 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 8.59±0.20°, 11.74±0.20°, 12.34±0.20°, 12.56±0.20°, 16.00±0.20°, 20.76±0.20°, 25.14±0.20° and 25.96±0.20°.
[0027] In one embodiment of the present application, the crystalline A of the compound of formula (I), its X-ray powder diffraction spectrum using Cu Kα radiation comprises 6, 7, 8, 9 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 8.59±0.20°, 11.74±0.20°, 12.34±0.20°, 12.56±0.20°, 16.00±0.20°, 17.20±0.20°, 19.40±0.20°, 20.76±0.20°, 25.14±0.20°, 25.96±0.20°, 27.48±0.20° and 31.68±0.20°.
[0028] In one embodiment of the present application, the crystalline A of the compound of formula (I), its X-ray powder diffraction spectrum using Cu Kα radiation comprises 9, 10, 11, 12 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 8.59±0.20°, 11.74±0.20°, 12.34±0.20°, 12.56±0.20°, 13.32±0.20°, 13.88±0.20°, 15.38±0.20°, 16.00±0.20°, 17.20±0.20°, 19.40±0.20°, 20.76±0.20°, 22.24±0.20°, 22.56±0.20°, 24.02±0.20°, 25.14±0.20°, 25.96±0.20°, 27.48±0.20°, 28.20±0.20°, 29.32±0.20°, 31.68±0.20°, 31.98±0.20° and 32.28±0.20°.
[0029] In one embodiment of the present application, the crystal A of the compound of formula (I) is prepared by using Cu The X-ray powder diffraction spectrum of Kα radiation comprises 12, 13, 14, 15 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 8.59±0.20°, 11.74±0.20°, 12.34±0.20°, 12.56±0.20°, 13.32±0.20°, 13.88±0.20°, 14.70±0.20°, 15.38±0.20°, 16.00±0.20°, 17.20±0.20°, 18.80±0.20°, 19.40±0.20°, 19.72±0.20°, 20.76±0.20°, 21.30±0.20°, 21.73±0.20°, 22.24±0.20°, 0.20°, 22.56±0.20°, 23.50±0.20°, 24.02±0.20°, 25.14±0.20°, 25.96±0.20°, 26.84±0.20°, 27.48±0.20°, 28.20±0.20°, 29.32±0.20°, 30.36±0.2 0°, 31.68±0.20°, 31.98±0.20°, 32.28±0.20°, 32.90±0.20°, 33.59±0.20°, 34.72±0.20°, 35.22±0.20°, 35.98±0.20°, 36.58±0.20° and 38.48±0.20°.
[0030] In one embodiment of the present application, the crystalline A of the compound of formula (I) has diffraction peaks at the following 2θ angles in its X-ray powder diffraction spectrum using Cu Kα radiation: 8.59±0.20°, 16.00±0.20°, 20.76±0.20°, 25.14±0.20° and 25.96±0.20°.
[0031] In one embodiment of the present application, the crystalline A of the compound of formula (I) has a diffraction peak at the following 2θ angles in its X-ray powder diffraction spectrum using Cu Kα radiation: 8.59±0.20°, 11.74±0.20°, 12.34±0.20°, 16.00±0.20°, 20.76±0.20°, 25.14±0.20° and 25.96±0.20°.
[0032] In one embodiment of the present application, the crystalline A of the compound of formula (I) has a diffraction peak at the following 2θ angles in its X-ray powder diffraction spectrum using Cu Kα radiation: 8.59±0.20°, 11.74±0.20°, 12.56±0.20°, 16.00±0.20°, 20.76±0.20°, 25.14±0.20° and 25.96±0.20°.
[0033] In one embodiment of the present application, the crystalline A of the compound of formula (I) has a diffraction peak at the following 2θ angles in its X-ray powder diffraction spectrum using Cu Kα radiation: 8.59±0.20°, 11.74±0.20°, 12.34±0.20°, 12.56±0.20°, 16.00±0.20°, 20.76±0.20°, 25.14±0.20° and 25.96±0.20°.
[0034] In one embodiment of the present application, the crystalline A of the compound of formula (I) has a diffraction peak at the following 2θ angles in its X-ray powder diffraction spectrum using Cu Kα radiation: 8.59±0.20°, 11.74±0.20°, 12.34±0.20°, 12.56±0.20°, 16.00±0.20°, 17.20±0.20°, 19.40±0.20°, 20.76±0.20°, 25.14±0.20°, 25.96±0.20°, 27.48±0.20° and 31.68±0.20°.
[0035] In one embodiment of the present application, the crystalline A of the compound of formula (I) has a diffraction peak at the following 2θ angles in its X-ray powder diffraction spectrum using Cu Kα radiation: 8.59±0.20°, 11.74±0.20°, 12.34±0.20°, 12.56±0.20°, 13.32±0.20°, 13.88±0.20°, 15.38±0.20°, 16.00±0.20°, 17.20±0.20°, 19.40±0.20° , 20.76±0.20°, 22.24±0.20°, 22.56±0.20°, 24.02±0.20°, 25.14±0.20°, 25.96±0.20°, 27.48±0.20°, 28.20±0.20°, 29.32±0.20°, 31.68±0.20°, 31.98±0.20° and 32.28±0.20°.
[0036] In one embodiment of the present application, the crystal A of the compound of formula (I) is prepared by using Cu The X-ray powder diffraction spectrum of Kα radiation has diffraction peaks at the following 2θ angles: 8.59±0.20°, 11.74±0.20°, 12.34±0.20°, 12.56±0.20°, 13.32±0.20°, 13.88±0.20°, 14.70±0.20°, 15.38±0.20°, 16.00±0.20°, 17.20±0.20°, 18.80±0.20°, 19.40±0.20°, 19.72±0.20°, 20.76±0.20°, 21.30±0.20°, 21.73±0.20°, 22.24±0.20°, 22.56±0. ±0.20°, 23.50±0.20°, 24.02±0.20°, 25.14±0.20°, 25.96±0.20°, 26.84±0.20°, 27.48±0.20°, 28.20±0.20°, 29.32±0.20°, 30.36±0.20°, 31.68±0.20°, 31.98±0.20°, 32.28±0.20°, 32.90±0.20°, 33.59±0.20°, 34.72±0.20°, 35.22±0.20°, 35.98±0.20°, 36.58±0.20° and 38.48±0.20°.
[0037] In one embodiment of the present application, the crystalline A of the compound of formula (I) has an X-ray powder diffraction spectrum using Cu Kα radiation as Figure 2 shown.
[0038] In one embodiment of the present application, the peak positions and relative intensities of characteristic peaks of the X-ray powder diffraction spectrum of the crystalline A of the compound of formula (I) using Cu Kα radiation are shown in Table 1.
[0039] Table 1 XRPD spectrum analysis data of compound A of formula (I)
[0040]
[0041]
[0042] In one embodiment of the present application, the crystalline A of the compound of formula (I) has a differential scanning calorimetry curve having an onset of an exothermic peak at 285.6±5°C.
[0043] In one embodiment of the present application, the crystalline A of the compound of formula (I) has a differential scanning calorimetry curve having an exothermic peak at 288.6±5°C.
[0044] In one embodiment of the present application, the crystal A of the compound of formula (I) has a differential scanning calorimetry (DSC) curve as follows: Figure 3 shown.
[0045] In one embodiment of the present application, the thermogravimetric analysis curve of the crystalline A of the compound of formula (I) shows a weight loss of 0.56% at 200.0±5°C.
[0046] In one embodiment of the present application, the crystal A of the compound of formula (I) has a thermogravimetric analysis curve such as Figure 4 shown.
[0047] The present application also provides a crystalline B of the compound of formula (I), whose X-ray powder diffraction spectrum using Cu Kα radiation comprises one or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 15.86±0.20°, 21.62±0.20° and 23.54±0.20°.
[0048] The present application also provides a crystalline B of the compound of formula (I), whose X-ray powder diffraction spectrum using Cu Kα radiation comprises 2, 3, 4 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 14.72±0.20°, 15.86±0.20°, 21.62±0.20°, 23.14±0.20°, 23.54±0.20° and 26.28±0.20°.
[0049] The present application also provides a crystalline B of the compound of formula (I), whose X-ray powder diffraction spectrum using Cu Kα radiation comprises 4, 5, 6, 7 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 13.66±0.20°, 14.72±0.20°, 15.86±0.20°, 18.30±0.20°, 21.62±0.20°, 23.14±0.20°, 23.54±0.20°, 25.80±0.20°, 26.28±0.20° and 27.96±0.20°.
[0050] The present application also provides a crystalline B of the compound of formula (I), whose X-ray powder diffraction spectrum using Cu Kα radiation comprises 7, 8, 9, 10 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 11.52±0.20°, 13.66±0.20°, 14.28±0.20°, 14.72±0.20°, 15.86±0.20°, 16.84±0.20°, 18.30±0.20°, 18.72±0.20°, 21.62±0.20°, 23.14±0.20°, 23.54±0.20°, 24.48±0.20°, 24.84±0.20°, 26.70±0.20°, 27.83±0.20°, 28.61±0.20°, 29.87±0.20°, 30. 5.80±0.20°, 26.28±0.20°, 27.96±0.20°, 28.40±0.20°, 28.84±0.20°, 29.82±0.20°, 30.22±0.20°, 31.74±0.20°, 32.04±0.20°, 32.69±0.20°, 33.90±0.20°, 34.50±0.20°, 35.02±0.20°, 36.08±0.20°, 36.94±0.20°, 37.46±0.20° and 37.92±0.20°.
[0051] The present application also provides Crystalline B of the compound of formula (I), whose X-ray powder diffraction spectrum using Cu Kα radiation has diffraction peaks at the following 2θ angles: 15.86±0.20°, 21.62±0.20° and 23.54±0.20°.
[0052] The present application also provides Crystalline B of the compound of formula (I), whose X-ray powder diffraction spectrum using Cu Kα radiation has diffraction peaks at the following 2θ angles: 14.72±0.20°, 15.86±0.20°, 21.62±0.20°, 23.14±0.20°, 23.54±0.20° and 26.28±0.20°.
[0053] The present application also provides crystalline B of the compound of formula (I), which has diffraction peaks at the following 2θ angles in its X-ray powder diffraction spectrum using Cu Kα radiation: 13.66±0.20°, 14.72±0.20°, 15.86±0.20°, 18.30±0.20°, 21.62±0.20°, 23.14±0.20°, 23.54±0.20°, 25.80±0.20°, 26.28±0.20° and 27.96±0.20°.
[0054] The present application also provides a crystalline B of the compound of formula (I), which has a diffraction peak at the following 2θ angles in its X-ray powder diffraction spectrum using Cu Kα radiation: 11.52±0.20°, 13.66±0.20°, 14.28±0.20°, 14.72±0.20°, 15.86±0.20°, 16.84±0.20°, 18.30±0.20°, 18.72±0.20°, 21.62±0.20°, 23.14±0.20°, 23.54±0.20°, 24.48±0.20°, 24.84±0.20°, 25.80±0.20°. °, 26.28±0.20°, 27.96±0.20°, 28.40±0.20°, 28.84±0.20°, 29.82±0.20°, 30.22±0.20°, 31.74±0.20°, 32.04±0.20°, 32.69±0.20°, 33.90±0.20°, 34.50±0.20°, 35.02±0.20°, 36.08±0.20°, 36.94±0.20°, 37.46±0.20° and 37.92±0.20°.
[0055] In one embodiment of the present application, the crystalline B of the compound of formula (I) has an X-ray powder diffraction spectrum using Cu Kα radiation as Figure 5 shown.
[0056] In one embodiment of the present application, the peak positions and relative intensities of characteristic peaks of the X-ray powder diffraction spectrum of the crystalline B of the compound of formula (I) using Cu Kα radiation are shown in Table 2.
[0057] serial number 2θ angle (±0.2°) Relative strength (%) serial number 2θ angle (±0.2°) Relative strength (%) 1 11.519 5.5 16 27.962 18.8 2 13.659 10.9 17 28.402 5.4 3 14.276 7.4 18 28.844 3.3 4 14.721 22.4 19 29.819 3.8 5 15.860 63.9 20 30.220 5.7 6 16.840 5.2 21 31.738 7.4 7 18.299 11.6 22 32.040 2.8 8 18.715 6.7 23 32.686 2.3 9 21.621 100.0 24 33.899 4.0 10 23.141 33.0 25 34.500 6.4 11 23.541 64.0 26 35.021 6.1 12 24.483 5.7 27 36.082 5.3 13 24.838 3.8 28 36.941 6.0 14 25.801 17.7 29 37.459 3.7 15 26.281 22.7 30 37.918 2.0
[0058] In one embodiment of the present application, the crystalline B of the compound of formula (I) has a differential scanning calorimetry curve having an onset of an exothermic peak at 287.4±5°C.
[0059] In one embodiment of the present application, the crystalline B of the compound of formula (I) has a differential scanning calorimetry curve having an exothermic peak at 290.6±5°C.
[0060] In one embodiment of the present application, the crystal B of the compound of formula (I) has a differential scanning calorimetry (DSC) curve as follows: Figure 6 shown.
[0061] In one embodiment of the present application, the thermogravimetric analysis curve of the crystalline B of the compound of formula (I) shows a weight loss of 0.70% at 200.0±5°C.
[0062] In one embodiment of the present application, the crystal B of the compound of formula (I) has a thermogravimetric analysis curve such as Figure 7 shown.
[0063] The present application also provides a crystalline C of the compound of formula (I), whose X-ray powder diffraction spectrum using Cu Kα radiation comprises 3, 4, 5, 6 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 6.46±0.20°, 18.78±0.20°, 19.82±0.20°, 20.98±0.20°, 21.70±0.20°, 23.30±0.20° and 24.92±0.20°.
[0064] The present application also provides a crystalline C of the compound of formula (I), whose X-ray powder diffraction spectrum using Cu Kα radiation comprises 6, 7, 8, 9 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 6.46±0.20°, 12.44±0.20°, 18.78±0.20°, 19.82±0.20°, 20.22±0.20°, 20.68±0.20°, 20.98±0.20°, 21.70±0.20°, 22.32±0.20°, 23.30±0.20°, 24.08±0.20°, 24.92±0.20° and 27.82±0.20°.
[0065] The present application also provides a crystalline C of the compound of formula (I), whose X-ray powder diffraction spectrum using Cu Kα radiation comprises 6, 7, 8, 9 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 6.46±0.20°, 12.44±0.20°, 18.78±0.20°, 19.82±0.20°, 20.22±0.20°, 20.68±0.20°, 20.98±0.20°, 21.70±0.20°, 22.68±0.20°, 23.30±0.20°, 24.08±0.20°, 24.92±0.20° and 27.82±0.20°.
[0066] The present application also provides a crystalline C of the compound of formula (I), whose X-ray powder diffraction spectrum using Cu Kα radiation comprises 6, 7, 8, 9 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 6.46±0.20°, 12.44±0.20°, 18.78±0.20°, 19.82±0.20°, 20.22±0.20°, 20.68±0.20°, 20.98±0.20°, 21.70±0.20°, 22.32±0.20°, 22.68±0.20°, 23.30±0.20°, 24.08±0.20°, 24.92±0.20° and 27.82±0.20°.
[0067] The present application also provides a crystalline C of the compound of formula (I), whose X-ray powder diffraction spectrum using Cu Kα radiation comprises 9, 10, 11, 12 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 6.46±0.20°, 9.94±0.20°, 12.44±0.20°, 16.32±0.20°, 18.78±0.20°, 19.82±0.20°, 20.22±0.20°, 20.68±0.20°, 2 0.98±0.20°, 21.70±0.20°, 22.32±0.20°, 22.68±0.20°, 23.30±0.20°, 24.08±0.20°, 24.92±0.20°, 26.14±0.20°, 26.86±0.20°, 27.82±0.20°, 28.52±0.20° and 29.34±0.20°.
[0068] The present application also provides a crystalline C of the compound of formula (I), whose X-ray powder diffraction spectrum using Cu Kα radiation comprises 12, 13, 14, 15 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 6.46±0.20°, 9.59±0.20°, 9.94±0.20°, 10.58±0.20°, 11.42±0.20°, 12.44±0.20°, 13.40±0.20°, 14.86±0.20°, 15.66±0.20°, 16.32±0.20°, 17.00±0.20°, 17.54±0.20°, 17.84±0.20°, 18.78±0.20°, 19.82±0.20°, 19.90±0.20°, 20. .20°, 20.22±0.20°, 20.68±0.20°, 20.98±0.20°, 21.70±0.20°, 22.32±0.20°, 22.68±0.20°, 23.30±0.20°, 24.08±0.20°, 24.92±0.20°, 26.14±0.20°, 26.86±0.20°, 27.34±0.20°, 27.82±0.20°, 28.52±0.20°, 29.34±0.20°, 30.18±0.20°, 31.36±0.20° and 32.36±0.20°.
[0069] The present application also provides crystalline C of the compound of formula (I), whose X-ray powder diffraction spectrum using Cu Kα radiation has diffraction peaks at the following 2θ angles: 6.46±0.20°, 18.78±0.20°, 19.82±0.20°, 20.98±0.20°, 21.70±0.20°, 23.30±0.20° and 24.92±0.20°.
[0070] The present application also provides crystalline C of the compound of formula (I), which has a diffraction peak at the following 2θ angles in its X-ray powder diffraction spectrum using Cu Kα radiation: 6.46±0.20°, 12.44±0.20°, 18.78±0.20°, 19.82±0.20°, 20.22±0.20°, 20.68±0.20°, 20.98±0.20°, 21.70±0.20°, 22.32±0.20°, 23.30±0.20°, 24.08±0.20°, 24.92±0.20° and 27.82±0.20°.
[0071] The present application also provides crystalline C of the compound of formula (I), which has a diffraction peak at the following 2θ angles in its X-ray powder diffraction spectrum using Cu Kα radiation: 6.46±0.20°, 12.44±0.20°, 18.78±0.20°, 19.82±0.20°, 20.22±0.20°, 20.68±0.20°, 20.98±0.20°, 21.70±0.20°, 22.68±0.20°, 23.30±0.20°, 24.08±0.20°, 24.92±0.20° and 27.82±0.20°.
[0072] The present application also provides crystalline C of the compound of formula (I), which has a diffraction peak at the following 2θ angles in its X-ray powder diffraction spectrum using Cu Kα radiation: 6.46±0.20°, 12.44±0.20°, 18.78±0.20°, 19.82±0.20°, 20.22±0.20°, 20.68±0.20°, 20.98±0.20°, 21.70±0.20°, 22.32±0.20°, 22.68±0.20°, 23.30±0.20°, 24.08±0.20°, 24.92±0.20° and 27.82±0.20°.
[0073] The present application also provides a crystalline compound C of formula (I), which has a diffraction peak at the following 2θ angles in its X-ray powder diffraction spectrum using Cu Kα radiation: 6.46±0.20°, 9.94±0.20°, 12.44±0.20°, 16.32±0.20°, 18.78±0.20°, 19.82±0.20°, 20.22±0.20°, 20.68±0.20°, 20.98±0.20° , 21.70±0.20°, 22.32±0.20°, 22.68±0.20°, 23.30±0.20°, 24.08±0.20°, 24.92±0.20°, 26.14±0.20°, 26.86±0.20°, 27.82±0.20°, 28.52±0.20° and 29.34±0.20°.
[0074] The present application also provides a crystalline C of the compound of formula (I), which has a diffraction peak at the following 2θ angles in its X-ray powder diffraction spectrum using Cu Kα radiation: 6.46±0.20°, 9.59±0.20°, 9.94±0.20°, 10.58±0.20°, 11.42±0.20°, 12.44±0.20°, 13.40±0.20°, 14.86±0.20°, 15.66±0.20°, 16.32±0.20°, 17.00±0.20°, 17.54±0.20°, 17.84±0.20°, 18.78±0.20°, 19.82±0.20°, 20.22±0.20°. 0°, 20.68±0.20°, 20.98±0.20°, 21.70±0.20°, 22.32±0.20°, 22.68±0.20°, 23.30±0.20°, 24.08±0.20°, 24.92±0.20°, 26.14±0.20°, 26.86±0.20°, 27.34±0.20°, 27.82±0.20°, 28.52±0.20°, 29.34±0.20°, 30.18±0.20°, 31.36±0.20° and 32.36±0.20°.
[0075] In one embodiment of the present application, the crystalline C of the compound of formula (I) has an X-ray powder diffraction spectrum using Cu Kα radiation as Figure 8 shown.
[0076] In one embodiment of the present application, the peak positions and relative intensities of characteristic peaks of the X-ray powder diffraction spectrum of the crystalline C of the compound of formula (I) using Cu Kα radiation are shown in Table 3.
[0077] serial number 2θ angle (±0.2°) Relative strength (%) serial number 2θ angle (±0.2°) Relative strength (%) 1 6.460 100.0 18 20.979 52.1 2 9.593 13.4 19 21.702 50.5 3 9.941 20.9 20 22.321 40.0 4 10.582 17.7 21 22.683 45.0 5 11.422 17.3 22 23.300 51.0 6 12.438 34.1 23 24.080 37.4 7 13.402 6.3 24 24.921 71.2 8 14.859 18.3 25 26.139 21.0 9 15.664 15.9 26 26.855 27.8 10 16.317 24.0 27 27.337 15.3 11 17.000 6.0 28 27.821 36.9 12 17.540 17.0 29 28.519 23.8 13 17.838 16.9 30 29.340 27.0 14 18.780 51.3 31 30.179 17.2 15 19.819 50.4 32 31.356 12.9 16 20.220 38.8 33 32.360 13.0 17 20.680 30.8
[0078] In one embodiment of the present application, the differential scanning calorimetry curve of the crystalline C of the compound of formula (I) has an onset of an exothermic peak at 261.6±5°C.
[0079] In one embodiment of the present application, the crystalline C of the compound of formula (I) has a differential scanning calorimetry curve having an exothermic peak at 267.5±5°C.
[0080] In one embodiment of the present application, the crystalline C of the compound of formula (I) has a differential scanning calorimetry (DSC) curve as follows: Fig. 9 shown.
[0081] The present application also provides a crystal D of the compound of formula (I), wherein the crystal D is an amorphous substance, and its X-ray powder diffraction spectrum using Cu Kα radiation is as follows: Figure 1 shown.
[0082] In one embodiment of the present application, the crystalline D of the compound of formula (I) is prepared from compound 1 in the presence of an organic solvent and hydrochloric acid.
[0083] In one embodiment of the present application, the crystalline D of the compound of formula (I) is obtained by stirring compound 1 in the presence of an organic solvent and hydrochloric acid, crystallizing, and filtering.
[0084] In one embodiment of the present application, in the preparation of the crystal D of the compound of formula (I), the organic solvent is selected from ethyl acetate.
[0085] In this application, the structure of compound 1 is shown below:
[0086]
[0087] In one embodiment of the present application, Crystal A of the compound of formula (I) is prepared from Crystal D of the compound of formula (I) in an organic solvent.
[0088] In one embodiment of the present application, the crystal A of the compound of formula (I) is prepared by heating and stirring the crystal D of the compound of formula (I) in an organic solvent.
[0089] In one embodiment of the present application, the crystal A of the compound of formula (I) is prepared by heating and stirring the crystal D of the compound of formula (I) in an organic solvent, further cooling to crystallize, and filtering.
[0090] In one embodiment of the present application, in the preparation of the crystal A of the compound of formula (I) above, the organic solvent is selected from acetone, tetrahydrofuran and ethyl acetate; preferably acetone.
[0091] In one embodiment of the present application, in the preparation of the above-mentioned crystal A of the compound of formula (I), the volume: molar ratio of the organic solvent to the crystal D of the compound of formula (I) is 2-10 mL:1 mmol; preferably 4-6 mL:1 mmol.
[0092] In one embodiment of the present application, in the preparation of the crystal A of the compound of formula (I) above, the heating temperature is 40 to 80°C; preferably 40 to 60°C.
[0093] In one embodiment of the present application, in the preparation of the crystal A of the compound of formula (I) above, the heating temperature is the reflux temperature of the organic solvent.
[0094] In one embodiment of the present application, in the preparation of the crystal A of the compound of formula (I) above, the stirring time is 10 to 48 hours; preferably 16 to 48 hours.
[0095] In one embodiment of the present application, in the preparation of the crystal A of the compound of formula (I) above, the temperature is lowered to 25-35°C, preferably 25-30°C for the crystallization.
[0096] On the other hand, the present application provides Crystals A of the compound of formula (I) prepared from Crystals D of the compound of formula (I) in an organic solvent, wherein Crystals A of the compound of formula (I) has the crystal characteristics of Crystals A above.
[0097] In one embodiment of the present application, Crystal A of the compound of formula (I) is prepared from Crystal D of the compound of formula (I) in one or more mixed solvents selected from acetone, tetrahydrofuran and ethyl acetate.
[0098] In one embodiment of the present application, Crystal A of the compound of formula (I) is prepared from Crystal D of the compound of formula (I) in acetone.
[0099] In some embodiments of the present application, the crystal B of the compound of formula (I) is prepared from the crystal D of the compound of formula (I) in an organic solvent.
[0100] In one embodiment of the present application, the crystal B of the compound of formula (I) is prepared by heating and stirring the crystal D of the compound of formula (I) in an organic solvent.
[0101] In one embodiment of the present application, the crystal B of the compound of formula (I) is prepared by heating and stirring the crystal D of the compound of formula (I) in an organic solvent, further cooling to crystallize, and filtering.
[0102] In one embodiment of the present application, in the preparation of the crystal B of the compound of formula (I) above, the organic solvent is selected from acetonitrile.
[0103] In one embodiment of the present application, in the preparation of the above-mentioned crystal B of the compound of formula (I), the volume: molar ratio of the organic solvent to the crystal D of the compound of formula (I) is 2-10 mL:1 mmol; preferably 4-6 mL:1 mmol.
[0104] In one embodiment of the present application, in the preparation of the crystal B of the compound of formula (I) above, the heating temperature is 30 to 80°C; preferably 40 to 60°C.
[0105] In one embodiment of the present application, in the preparation of the crystal B of the compound of formula (I) above, the heating temperature is the reflux temperature of the organic solvent.
[0106] In one embodiment of the present application, in the preparation of the crystal B of the compound of formula (I) above, the stirring time is 10 to 48 hours, preferably 16 to 48 hours.
[0107] In one embodiment of the present application, in the preparation of the crystal B of the compound of formula (I) above, the temperature is lowered to 25-35°C, preferably 25-30°C for the crystallization.
[0108] On the other hand, the present application provides Crystals B of the compound of formula (I) prepared from Crystals D of the compound of formula (I) in an organic solvent, wherein Crystals B of the compound of formula (I) has the crystal characteristics of Crystals B described above.
[0109] In one embodiment of the present application, Crystalline B of the compound of formula (I) is prepared from Crystalline D of the compound of formula (I) in acetonitrile.
[0110] In one embodiment of the present application, the crystalline C of the compound of formula (I) is prepared by freeing the crystalline D of the compound of formula (I) in the presence of an organic solvent and a base, and then in the presence of hydrochloric acid.
[0111] In one embodiment of the present application, the crystal C of the compound of formula (I) is prepared by freeing the crystal D of the compound of formula (I) in the presence of an organic solvent and a base, separating the liquid, stirring in the presence of hydrochloric acid, crystallizing, and filtering.
[0112] In one embodiment of the present application, in the preparation of the above-mentioned crystal C of the compound of formula (I), the organic solvent of the freeing step is selected from ethyl acetate.
[0113] In one embodiment of the present application, in the preparation of the above-mentioned crystal C of the compound of formula (I), the base in the freeing step is selected from sodium bicarbonate, sodium hydroxide, potassium hydroxide, potassium bicarbonate and sodium carbonate; preferably sodium bicarbonate.
[0114] In one embodiment of the present application, in the preparation of the above-mentioned Crystal C of the compound of formula (I), the base in the freeing step is in the form of a saturated aqueous solution of the base.
[0115] In one embodiment of the present application, in the preparation of the above-mentioned crystal C of the compound of formula (I), the mole: volume: volume ratio of the crystal D of the compound of formula (I) in the free step and the saturated aqueous solution of the organic solvent and the base is 1 mmol: 12-20 mL: 4-10 mL; preferably 1 mmol: 12-16 mL: 4-6 mL.
[0116] In one embodiment of the present application, in the preparation of the above-mentioned crystal C of the compound of formula (I), the freeing step is carried out under stirring for 8 to 12 minutes, preferably 10 minutes.
[0117] In one embodiment of the present application, in the preparation of the crystal C of the compound of formula (I) above, the hydrochloric acid is in an organic solvent, and the organic solvent is selected from ethyl acetate, chloroform, carbon tetrachloride and dioxane; preferably ethyl acetate.
[0118] In one embodiment of the present application, in the preparation of the crystal C of the compound of formula (I) above, the equivalent ratio of the crystal D of the compound of formula (I) to the hydrochloric acid is 1:0.85.
[0119] On the other hand, the present application provides Crystals C of the compound of formula (I) prepared from Crystals D of the compound of formula (I) in an organic solvent, wherein Crystals C of the compound of formula (I) has the crystal characteristics of the above Crystals C.
[0120] In one embodiment of the present application, Crystalline C of the compound of formula (I) is prepared from Crystalline D of the compound of formula (I) in ethyl acetate.
[0121] The hydrochloric acid described in the present application may be in a standby form in which HCl gas is introduced into an organic solvent to prepare a solution, and the organic solvent is selected from ethyl acetate, chloroform, carbon tetrachloride and dioxane; preferably ethyl acetate.
[0122] On the other hand, the present application provides a crystalline composition of a compound of formula (I), wherein the crystals of the compound of formula (I) account for more than 50% by weight of the crystalline composition, preferably more than 75%, more preferably more than 90%, and most preferably more than 95%. The crystalline composition may also contain a small amount of other crystalline or non-crystalline forms of the compound of formula (I).
[0123] On the other hand, the present application provides a pharmaceutical composition, which comprises a therapeutically effective amount of the compound of formula (I) above, a crystal of the compound of formula (I) above, or a crystalline composition of the compound of formula (I) above; the pharmaceutical composition may comprise at least one pharmaceutically acceptable carrier or other excipient.
[0124] On the other hand, the present application provides the use of the compound of formula (I), the crystal of the compound of formula (I), the crystalline composition of the compound of formula (I), or the pharmaceutical composition in the preparation of a drug for preventing or treating PARP receptor-related diseases.
[0125] On the other hand, the present application provides the use of the compound of formula (I), the crystal of the compound of formula (I), the crystalline composition of the compound of formula (I), or the pharmaceutical composition for preventing or treating PARP receptor-related diseases.
[0126] On the other hand, the present application provides a method for preventing or treating PARP receptor-related disorders, which comprises administering to a mammal in need thereof a therapeutically effective amount of the compound of formula (I), the crystal of the compound of formula (I), the crystalline composition of the compound of formula (I), or the pharmaceutical composition.
[0127] In another aspect, the present application provides the compound of formula (I) above, a crystal of the compound of formula (I), a crystalline composition of the compound of formula (I) above, or the pharmaceutical composition above, which is used as a PARP inhibitor.
[0128] On the other hand, the present application provides the compound of formula (I), the crystal of the compound of formula (I), the crystalline composition of the compound of formula (I), or the pharmaceutical composition for preventing or treating PARP receptor-related disorders.
[0129] In one embodiment of the present application, the mammal is a human.
[0130] In one embodiment of the present application, the PARP receptor-related disorder is selected from tumors or cancers.
[0131] In one embodiment of the present application, the PARP receptor-related disorder is selected from breast cancer.
[0132] On the other hand, the present application provides a method for preparing a compound of formula (I) or a crystal thereof, wherein the method for preparing the crystal is: heating and stirring an amorphous substance of the compound of formula (I) in an organic solvent, further cooling and crystallizing, and filtering to prepare the crystal; the amorphous substance of the compound of formula (I) has an X-ray powder diffraction spectrum using Cu Kα radiation such as Figure 1 As shown; in the preparation method of the crystal, the organic solvent is selected from acetone, tetrahydrofuran and ethyl acetate; preferably acetone. Preferably, the crystal is crystal A.
[0133] In one embodiment of the present application, in the method for preparing the crystal, the volume: molar ratio of the organic solvent to the amorphous substance of the compound of formula (I) is 2-10 mL:1 mmol; preferably 4-6 mL:1 mmol.
[0134] In one embodiment of the present application, in the method for preparing the crystal, the amorphous compound of the formula (I) is obtained by stirring compound 1 in the presence of an organic solvent and hydrochloric acid, crystallizing, and filtering; the organic solvent is selected from ethyl acetate; and compound 1 has the following structure:
[0135]
[0136] In the present application, the pharmaceutical composition can be prepared into a certain dosage form for administration, preferably oral administration, parenteral administration (including subcutaneous, intramuscular and intravenous), rectal administration, etc. For example, dosage forms suitable for oral administration include tablets, capsules, granules, powders, pills, powders, lozenges, syrups or suspensions; dosage forms suitable for parenteral administration include aqueous or non-aqueous injection solutions or emulsions; dosage forms suitable for rectal administration include suppositories using hydrophilic or hydrophobic carriers. As needed, the above dosage forms can also be prepared into dosage forms suitable for rapid release, delayed release or regulated release of the active ingredient.
[0137] The pharmaceutical composition of the present application can be manufactured by methods well known in the art, such as conventional mixing methods, dissolution methods, granulation methods, sugar-coated pill making methods, grinding methods, emulsification methods, freeze-drying methods, etc.
[0138] The crystals described in the present application may be in the form of a non-solvate or a solvate, such as a hydrate.
[0139] In this application, the X-ray powder diffraction spectrum of the sample was measured under the following conditions: Instrument: Dandong Haoyuan DX-2700BH X-ray diffractometer; Target: Cu: Kα; Wavelength 2θ angle range: 3-40°; scattering slit: 1mm; detector slit: 0.3mm; anti-scattering slit: 1mm; Cu target tube voltage and tube current: 40KV, 30mA.
[0140] In the present application, the DSC spectrum is measured under the following conditions: instrument: METTLERTOLEDO DSC1 differential scanning calorimeter; temperature range: 40-350°C; heating rate: 10°C / min.
[0141] In the present application, TGA thermogravimetric analysis was measured under the following conditions: instrument: TATGA550 thermogravimetric analyzer; gas flow rate: 40 mL / min; temperature range: 40-500° C.; heating rate: 10° C. / min.
[0142] It should be noted that in the powder X-ray diffraction spectrum, the position of the peak or the relative intensity of the peak may vary due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal, there may be an error in the position of the peak, and the measurement error of the 2θ value is ±0.2. Therefore, when determining each crystal, this error should be taken into account, and it also belongs to the scope of this application within the error.
[0143] It should be noted that for the same type of crystal, the position of the endothermic peak of DSC may be different due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal, the position of the endothermic peak may have an error, which may be ±5°C. Therefore, when determining each crystal, this error should be taken into account, and the error is also within the scope of this application.
[0144] It should be noted that for the same type of crystal, the position of the weight loss temperature of TGA may be different due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal, the position of the weight loss temperature may have an error, and the error may be ±5°C. Therefore, when determining each crystal, this error should be taken into account, and the error is also within the scope of this application.
[0145] Technical Effects
[0146] The compound 1 described in the present application has a strong inhibitory activity against the PARP1 enzyme, and has excellent antiproliferative activity against the BRCA1 mutated MDA-MB-436 cells, and has no inhibitory activity against the BRCA wild-type MDA-MB-231 cells, showing that the compound of the present application has excellent selectivity and safety. The compound 1 of the present application also has a certain inhibitory effect on poly ADP ribosylation. In addition, the pharmacokinetic properties of the compound 1 of the present application are excellent, the metabolism in the body is stable, and the bioavailability is high. In general, the compounds of the present application are not only excellent in activity and easy to synthesize, but also have excellent pharmacokinetic properties.
[0147] The crystal properties of the compound of formula (I) described in the present application are stable, and they show good stability under conditions of high humidity and high temperature, and also show good stability under long-term test conditions. The crystals of the compound of formula (I) described in the present application have advantages in terms of drug activity, pharmacokinetics, bioavailability, stability, purity, and ease of preparation, so as to meet the needs of drugs in production, storage, transportation, and formulation.
[0148] Definition and Description
[0149] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. A particular phrase or term should not be considered to be uncertain or unclear in the absence of a special definition, but should be understood according to its ordinary meaning. When a trade name appears in this article, it is intended to refer to its corresponding commercial product or its active ingredient.
[0150] "Mammal" includes humans and domestic animals such as laboratory mammals and household pets (e.g., cats, dogs, pigs, sheep, cattle, goats, horses, rabbits), and non-domesticated mammals, such as wild mammals, etc.
[0151] The term "pharmaceutical composition" refers to a preparation of the present invention compound and a medium generally accepted in the art for delivering biologically active compounds to mammals, such as humans. The medium includes all pharmaceutically acceptable carriers for its use. The pharmaceutical composition facilitates the administration of the compound to an organism.
[0152] The term "therapeutically effective amount" refers to a sufficient amount of a drug or pharmaceutical agent that is non-toxic but can achieve the desired effect. The determination of the effective amount varies from person to person, depending on the age and general condition of the recipient, and also on the specific active substance. The appropriate effective amount in each case can be determined by a person skilled in the art based on routine experiments.
[0153] The term "treatment" means administering the compound or formulation described herein to improve or eliminate a disease or one or more symptoms associated with the disease, and includes:
[0154] (i) inhibiting a disease or disease state, i.e. arresting its development;
[0155] (ii) ameliorating a disease or condition, even if causing regression of the disease or condition.
[0156] The term "prevention" means administering the compounds or formulations described herein to prevent a disease or one or more symptoms associated with the disease, and includes preventing a disease or disease state from occurring in a mammal, particularly when such mammal is susceptible to the disease state but has not yet been diagnosed as having the disease state.
[0157] In the present application, "pharmaceutically acceptable carrier" refers to those carriers that are administered together with the active ingredient, have no significant irritation to the organism, and do not impair the biological activity and performance of the active compound. For other information about the carrier, reference may be made to Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005), the contents of which are incorporated herein by reference.
[0158] In the present application, "room temperature" refers to 20°C to 30°C.
[0159] As used herein, "EtOAc" stands for ethyl acetate.
[0160] The word "comprise" or "comprises" and its English variations such as comprises or comprising or equivalents should be understood as an open, non-exclusive meaning, that is, "including but not limited to", meaning that in addition to the listed elements, components and steps, other unspecified elements, components and steps may also be included.
[0161] Herein, singular terms include plural referents and vice versa unless the context clearly dictates otherwise.
[0162] Herein, unless otherwise indicated, each parameter value (including 2θ values, reaction conditions) is deemed to be modified by the term "about" to reflect the measurement error that exists for each value, for example, there is an error of ±5% relative to a given value.
[0163] For the purpose of description and disclosure, all patents, patent applications and other identified publications are expressly incorporated herein by reference. These publications are provided only because they are disclosed prior to the filing date of the present application. All statements regarding the dates of these documents or the representations of the contents of these documents are based on the information available to the applicant and do not constitute any admission as to the correctness of the dates of these documents or the contents of these documents. Furthermore, any reference to these publications herein does not constitute an admission that the publications are part of the common general knowledge in the art in any country. BRIEF DESCRIPTION OF THE DRAWINGS
[0164] Figure 1 It is the XRPD spectrum of the crystal D of the compound of formula (I).
[0165] Figure 2 The XRPD spectrum of the compound of formula (I) crystalline A prepared by method 1 in Example 2.
[0166] Figure 3 It is the DSC spectrum of the crystal A of the compound of formula (I).
[0167] Figure 4 This is the TGA spectrum of crystal A of compound of formula (I).
[0168] Figure 5 It is the XRPD spectrum of the crystal B of the compound of formula (I).
[0169] Figure 6 It is the DSC spectrum of the crystal B of the compound of formula (I).
[0170] Figure 7 This is the TGA spectrum of crystal B of compound of formula (I).
[0171] Figure 8 It is the XRPD spectrum of the crystal C of the compound of formula (I).
[0172] Fig. 9 It is the DSC spectrum of the crystal C of the compound of formula (I).
[0173] Fig.10 It is a three-dimensional structural ellipsoid diagram of crystal A of compound of formula (I). DETAILED DESCRIPTION
[0174] The present application is described in detail below by examples, but it is not meant to limit the present application in any adverse way. The compounds of the present application can be prepared by a variety of synthesis methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by the combination of the specific embodiments and other chemical synthesis methods, and the equivalent substitution methods well known to those skilled in the art, and preferred embodiments include but are not limited to the embodiments of the present application. It will be apparent to those skilled in the art that various changes and improvements are made to the specific embodiments of the present application without departing from the spirit and scope of the present application.
[0175] Example 1: Preparation of Compound 1
[0176]
[0177] Step A: 1-1 (25 g, 129.42 mmol) was dissolved in dichloromethane (250 ml), and triethylamine (26.19 g, 258.83 mmol), 4-dimethylaminopyridine (3.16 g, 25.88 mmol), and di-tert-butyl dicarbonate (31.07 g, 142.36 mmol) were added at 0°C. The system was stirred at 25°C for two hours. Saturated aqueous ammonium chloride solution (80 ml*3) and saturated brine (50 ml*2) were added to the system for washing, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 1-2.
[0178] Step B: Dissolve diisopropylamine (13.80 g, 136.38 mmol) in tetrahydrofuran (60 ml), and add 2.5 M n-butyl lithium (47.73 ml) dropwise to the above system at -78°C under nitrogen protection, and complete the dripping within half an hour. The reaction solution is stirred at 0°C for half an hour, and then the above reaction solution is added dropwise to another three-necked flask containing 1-2 (25 g, 285.14 mmol) and triisopropyl borate (24.05 g, 127.86 mmol) in tetrahydrofuran (200 ml) at 0°C under nitrogen protection, and complete the dripping quickly at 0°C. The reaction solution is stirred at 0°C for 1 hour. The system was then quenched with acetic acid solution (50 ml), diluted with water (60 ml), extracted with ethyl acetate (60 ml * 3), the organic phases were combined, washed with saturated aqueous ammonium chloride solution (50 ml * 3) and saturated brine (40 ml * 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a crude product. The crude product was slurried with acetonitrile (100 ml) and aqueous solution (300 ml), and the filter cake was pulled dry with an oil pump to obtain 1-3.
[0179] Step C: 1-3 (45 g, 133.49 mmol) was added to a trifluoroacetic acid (200 ml) solution at 0°C in three portions, and the system was stirred for one hour under nitrogen protection at 0°C. The reaction solution was then poured into ice water (300 ml), solids precipitated, and a filter cake was obtained, which was concentrated under reduced pressure using an oil pump to obtain 1-4.
[0180] Step D: In a three-necked flask containing magnesium chips (2.58 g, 105.98 mmol) and iodine (489.05 mg, 1.93 μmol), 1-5 (25 g, 105.98 mmol) was dissolved in tetrahydrofuran (100.00 ml), and added dropwise to the above system at 70°C under nitrogen protection, and the mixture was completed within half an hour. The reaction solution was stirred at 70°C for 1 hour, and then the system was cooled to 20°C. The above reaction solution was added dropwise to another three-necked flask containing tert-butyl 2-oxopyrrolidine-1-carboxylate (17.84 g, 96.34 mmol) in tetrahydrofuran (150 ml) at -70°C under nitrogen protection, and the mixture was completed within half an hour. The reaction solution was stirred at -70°C for 2 hours, and then heated to 10°C and stirred for 1 hour. The system was quenched with saturated aqueous ammonium chloride solution (60 mL), extracted with ethyl acetate (60 mL*3), the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column to obtain 1-6.
[0181] Step E: 1-6 (50 g, 146.10 mmol) was added to trifluoroacetic acid (250 ml) at 0°C. The system was stirred at 15°C for 12 hours. The reaction solution was adjusted to pH = 14 with 40% sodium hydroxide aqueous solution, and a yellow solid precipitated. The solid was filtered, and the filter cake was washed with a small amount of water and dried to obtain 1-7.
[0182] Step F: 1-7 (15 g, 66.94 mmol) was dissolved in tetrahydrofuran (150 ml). The system was cooled to -78°C under nitrogen protection, and boron trifluoride etherate (19 g, 133.87 mmol) was added dropwise to the above system, and the dripping was completed within half an hour. The system was stirred at -78°C for half an hour. Then methyl lithium solution (1.6M, 83.67 ml) was added dropwise to the above system. The system was slowly heated to 78°C and stirred for 19.5 hours. The system was cooled to room temperature and quenched with saturated sodium bicarbonate aqueous solution (100 ml), water (30 ml) was added, and it was extracted with ethyl acetate (80 ml*3), and the organic phases were combined, washed with saturated brine (30*2 ml), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 1-8.
[0183] Step G: 1-8 (16 g, 66.63 mmol) was dissolved in dichloromethane (150 ml), triethylamine (20.23 g, 199.88 mmol) was added at 0°C, followed by di-tert-butyl dicarbonate (29.08 g, 133.26 mmol). The system was stirred at 15°C for 1 hour. The system was concentrated under reduced pressure and dried, saturated aqueous ammonium chloride solution (60 ml) was added, and the mixture was extracted with ethyl acetate (80 ml*3), the combined organic phases were washed with saturated brine (30*3 ml), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 1-9.
[0184] Step H: 1-9 (9 g, 26.45 mmol) and 1-4 (7.52 g, 31.74 mmol) were dissolved in ethylene glycol dimethyl ether (100 ml) and water (20 ml), and sodium bicarbonate (6.67 g, 79.35 mmol) and 1,1-di(tert-butylphosphino)ferrocenepalladium chloride (1.72 g, 2.65 mmol) were added. Nitrogen was replaced three times, and the system was stirred at 80°C for twelve hours under nitrogen protection. The system was concentrated under reduced pressure and dried, and a saturated aqueous solution of common salt (60 ml) was added, and extracted with ethyl acetate (60 ml*3). The combined organic phases were washed with saturated brine (50 ml), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column to obtain 1-10.
[0185] Step I: Add oxalyl chloride (5.61 g, 44.20 mmol) to dichloromethane (150 ml), and slowly add N,N-dimethylformamide (4.85 g, 66.30 mmol) at 0°C under nitrogen protection. The system is stirred at 0°C for 15 minutes. Then 1-10 (10 g, 22.10 mmol) is dissolved in dichloromethane (50 ml) and added to the reaction system at 0°C. The system is stirred at 15°C for 0.5 hours. The reaction solution is quenched with 10% aqueous ammonium acetate (100 ml) and tetrahydrofuran (100 ml), extracted with ethyl acetate (45 ml*2), and the combined organic phases are washed with saturated aqueous ammonium chloride (50 ml*3) and saturated brine (50 ml*3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 1-11.
[0186] Step J: 1-11 (10.62 g, 22.10 mmol) was dissolved in dichloromethane (80 ml), and triethylamine (6.71 g, 66.30 mmol), di-tert-butyl dicarbonate (9.65 g, 44.20 mmol) and 4-dimethylaminopyridine (810.01 mg, 6.63 mmol) were added at 0°C. The system was stirred at 15°C for one hour. The system was concentrated under reduced pressure and dried, and saturated aqueous ammonium chloride solution (60 ml) was added and extracted with ethyl acetate (60 ml*3). The combined organic phases were washed with saturated brine (30*3 ml), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 1-12.
[0187] Step K: 1-12 (12.75 g, 21.96 mmol) was dissolved in tetrahydrofuran (100 ml) and methanol (25 ml). The system was cooled to 0°C and sodium borohydride (1.25 g, 32.94 mmol) was added. The system was stirred at 0°C for 40 minutes. The system was quenched with saturated aqueous ammonium chloride solution (80 ml), extracted with ethyl acetate (80 ml*2), and the combined organic phases were washed with water (50 ml), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 1-13.
[0188] Step L: 1-13 (12.79 g, 21.95 mmol) was dissolved in dichloromethane (150 ml), triethylamine (4.44 g, 43.90 mmol) was added, and then methanesulfonyl chloride (3.02 g, 26.34 mmol) was added at 0°C under nitrogen protection. The system was stirred at 0°C for one hour. The system was concentrated under reduced pressure and dried, and ethyl acetate (80 ml) was added. The organic phase was washed with saturated aqueous ammonium chloride (30 ml*2) and saturated brine (20 ml*2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 1-14.
[0189] Step M: 1-14 (14.45 g, 21.87 mmol) was dissolved in N, N-dimethylformamide (150 ml), and sodium carbonate (4.64 g, 43.74 mmol) and N-hydroxyphthalimide (5.35 g, 32.80 mmol) were added. The system was stirred at 65°C for twelve hours. Aqueous solution (60 ml) was added to the system and extracted with ethyl acetate (80 ml*2). The organic phase was washed with saturated aqueous ammonium chloride solution (50 ml*3) and saturated brine (50 ml*3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column to obtain 1-15.
[0190] Step N: Dissolve 1-15 (15 g, 20.61 mmol) in methanol (200 ml) and add 98% hydrazine hydrate (3.10 g, 61.83 mmol). Stir the system at 65°C for two hours under nitrogen protection. Filter the system and concentrate under reduced pressure to obtain a residue. The residue is purified by silica gel column to obtain 1-16.
[0191] Step O: Compound 1-16 was separated by chiral HPLC column (separation column AD-H (250 mm*30 mm, 5 μm); mobile phase [0.1% ammonia water in isopropanol]; elution gradient 25%-25%, 2.7 min; 400 min) to give 1_AA (retention time = 2.161 min, ee value (enantiomeric excess): 100%) and 1_BB (retention time = 2.353 min, ee value (enantiomeric excess): 97%).
[0192] Method for measuring ee value (enantiomeric excess): Analytical column: Amycoat 50×4.6mm ID, 3μm; Mobile phase: 10%-20% isopropanol (0.05% diethylamine) in CO 2 Medium; flow rate: 3mL / min; wavelength: 220nm.
[0193] Step P: 1_AA was deprotected with trifluoroacetic acid to obtain compound 1 (time = 3.461 min), ee value (enantiomeric excess): 98%.
[0194] Method for measuring ee value (enantiomeric excess): Separation column: Chiralcel Cellucoat 50×4.6mm ID, 3um Mobile phase: 10%-40% isopropanol (0.05% diethylamine) in CO 2 ; Flow rate: 3mL / min; Wavelength: 220nm.
[0195] Compound 1: 1 H NMR (400 MHz, deuterated dimethyl sulfoxide) δ = 12.00 (br s, 1H), 11.30 (br s, 1H), 8.23 (br s, 1H), 7.62 (br d, J = 7.75 Hz, 4H), 7.45 (br d, J = 9.13 Hz, 2H), 5.44 (br d, J = 14.51 Hz, 1H), 5.14-5.31 (m, 1H), 2.99-3.42 (m, 2H), 1.89-2.23 (m, 4H), 1.53 (br s, 3H).
[0196] Example 2: Preparation of Crystals A, B, C and D of Compound of Formula (I)
[0197]
[0198] Preparation of Crystal D:
[0199] Step 1: At -40 to -20°C, HCl gas was introduced into EtOAc (100 mL) to prepare a HCl / EtOAc (ethyl acetate hydrochloride, 7 mol, 100 mL) solution.
[0200] Step 2: At -20 to -10°C, compound 1_AA (10 g, 17.68 mmol) was added to the above solution in batches. After the addition, the cooling bath was removed and the temperature was naturally raised to about 20°C. Stirring was continued for 3 h, and a large amount of solid precipitated.
[0201] Step 3: Filter, wash three times with ethyl acetate (30 ml*3), collect the solid, and dry it in an oven for 16 h to obtain crystalline D of the compound of formula (I).
[0202] 1 H NMR (400 MHz, DMSO-d 6 )δ12.15(br s, 1H), 11.30(s, 1H), 10.45(br s, 1H), 9.29(br s, 1H), 7.61-7.75(m, 4H), 7.39-7.51(m, 2H), 5.45(br d, J=14.79Hz, 1H), 5.23 (brdd, J=7.40, 14.73Hz, 1H), 3.29-3.36 (m, 2H), 2.34-2.45 (m, 1H), 2.14-2.30 (m, 2H), 2.05 (br d, J=4.16Hz, 1H), 1.60 (s, 3H).
[0203] Preparation of Crystal A:
[0204] Method 1:
[0205] Crystal D (1 g, 2.49 mmol) of the compound of formula (I) was added to 10 ml of acetone, refluxed with stirring for 16 h, then cooled to about 30°C, the solid was collected by filtration, and dried at 35-40°C to obtain Crystal A of the compound of formula (I).
[0206] 1 HNMR (400 MHz, DMSO-d 6)δ=12.24-12.06 (m, 1H), 11.41-11.22 (m, 1H), 10.39 (brs, 1H), 9.50-8.97 (m, 1H), 7.79-7.59 (m, 4H), 7.55-7.33 (m, 2H), 5.56-5.37 (m, 1H), 5.31-5.15 (m, 1H), 3.50-3.42 (m, 1H), 3.36-3.29 (m, 1H), 2.45-2.34 (m, 1H), 2.15 (br s, 2H), 2.14-2.01 (m, 1H), 1.61 (s, 3H).
[0207] Method 2:
[0208] Crystal D (200 mg, 0.50 mmol) of the compound of formula (I) was added to 2 ml of ethyl acetate, refluxed and stirred at 40°C for 48 h, and then the solid was collected by filtration and dried at 35-40°C to obtain Crystal A of the compound of formula (I).
[0209] Method 3:
[0210] Crystal D (200 mg, 0.50 mmol) of the compound of formula (I) was added to 2 ml of tetrahydrofuran, refluxed and stirred at 40°C for 48 h, then the solid was collected by filtration and dried at 35-40°C to obtain Crystal A of the compound of formula (I).
[0211] Preparation of Crystal B:
[0212] Crystal D (1 g, 2.49 mmol) of the compound of formula (I) was added to 10 ml of acetonitrile, refluxed and stirred for 16 h, then cooled to about 30° C., the solid was collected by filtration and dried. The solid was Crystal B of the compound of formula (I).
[0213] 1 H NMR (400 MHz, DMSO-d 6 )δ=12.14(d, J=3.1Hz, 1H), 11.30(s, 1H), 10.47(br s, 1H), 9.27(br d, J=9.5Hz, 1H), 7.76-7.60 (m, 4H), 7.45 (dt, J=2.3, 9.5Hz, 2H), 5.56-5.38 (m, 1H), 5.22 (dd, J=7.9, 14.8Hz, 1H), 3.49-3.40 (m, 1H), 3.34 (br d, J=7.0Hz, 1H), 2.38(br d, J=8.0Hz, 1H), 2.29-2.13 (m, 2H), 2.08 (s, 1H), 2.07 (s, 1H), 2.07-1.99 (m, 1H), 1.59 (s, 3H).
[0214] Preparation of Crystalline C:
[0215] Add crystalline D (10 g, 2.49 mmol) of the compound of formula (I) to 40 ml of ethyl acetate, then add saturated NaHCO3 solution (15 ml) and stir for 10 minutes. After separation and drying, add the obtained solid to a suitable reaction bottle and cool to -20°C. Then slowly add ethyl acetate hydrochloride (0.5 M, 4.23 ml, 0.85 eq). After the addition is completed, return to room temperature naturally and react for 2.5 hours. Then filter and collect the solid, and dry it. The solid is crystalline C of the compound of formula (I).
[0216] 1 H NMR (400 MHz, DMSO-d 6 )δ12.11-12.19(m, 1H), 11.30(s, 1H), 10.41(br s, 1H), 9.20-9.35(m, 1H), 7.63-7.72(m, 4H), 7.42-7.50(m, 2H), 5.45(br d, J=15.28Hz, 1H), 5.23 (dd, J=7.15, 14.86Hz, 1H), 3.44-3.66 (m, 1H), 3.31-3.3 6(m, 1H), 2.33-2.45(m, 1H), 2.14-2.29(m, 2H), 2.00-2.11(m, 1H), 1.60(s, 3H).
[0217] Experimental Example 1: Stability test of crystals A and B of compound of formula (I)
[0218] 1. Preliminary stability study
[0219] Study conditions: At 60°C and 75% humidity, the stability of crystal A and crystal B were studied simultaneously. The results are as follows:
[0220]
[0221] 2. Accelerated testing
[0222] Test conditions: The crystal A sample of the compound of formula (I) was placed in a double-layer medicinal low-density polyethylene bag, each layer of the medicinal low-density polyethylene bag was sealed with a buckle, and then placed in an aluminum foil bag and heat-sealed. The accelerated test was carried out at 40°C ± 2°C / 75 ± 5% RH. The results are as follows:
[0223]
[0224] Conclusion: Crystal A and Crystal B of the compound of formula (I) have good stability.
[0225] Experimental Example 2: PARP-1 Enzyme Experiment
[0226] Experimental materials: test compound, HT Universal Chemiluminescent PARP Assay kit (kit) purchased from TREVIGEN, PBS (phosphate buffer saline) purchased from Vicente, Triton X-100 purchased from McLean, Envision multi-label analyzer (PerkinElmer).
[0227] Element volume Storage conditions PARP-HSA, 10 U / μl 50μL -20℃ 20X PARP Buffer (2 vials) 2 × 500 μL -80℃ 10X PARP Cocktail 300μ1 -80℃ Histone-Coated White Strip Wells 96-well 4℃ 10X Strep-Diluent 2ml 4℃ Strep-HRP 30μl 4℃ <![CDATA[PeroxyGlow TM A]]> 6mL 4℃ <![CDATA[PeroxyGlow TM B]]> 6mL 4℃ 10X Activated DNA 300μL -20℃
[0228] Experimental steps:
[0229] (I) Reagent preparation:
[0230] 1. Washing solution: Add Triton X-100 to 1x PBS. The final concentration of Triton X-100 is 0.1%.
[0231] 2. 1x PARP buffer: Take the 20x PARP buffer in the kit and dilute it 20 times with water to prepare 1x PARP buffer. This buffer is used to prepare compounds, enzyme solutions, and substrate solutions.
[0232] 3. 1x Strep-Diluent solution: Dilute the 10x Strep-Diluent in the kit 10 times with water to prepare a 1x Strep-Diluent solution.
[0233] (II) Preparation of test compounds:
[0234] The test compound was diluted from 200 μM to 2.56 nM, and the DMSO concentration was 100%. 2 μL of each inhibitor concentration gradient was taken to the middle plate of the compound, and 38 μL of 1x PARP buffer was added and mixed for later use. At this time, the DMSO concentration was 5%.
[0235] (III) Experimental methods:
[0236] a) Add 50 μL of 1x PARP buffer to each well of the test plate and incubate at 25°C for 30 minutes.
[0237] b) After the incubation is finished, the liquid in the test plate is discarded, and 10 μL of each compound of each concentration gradient is taken from the compound intermediate plate and added to the test plate. Set up a double-well experiment.
[0238] c) Add 15 μL of enzyme solution (0.5 IU) to each well of the test plate. Incubate the compound and enzyme at 25°C for 10 minutes.
[0239] d) After the incubation, 25 μL of 1× PARP Cocktail was added to each well of the test plate. The 25 μL 1× PARP Cocktail included 2.5 μL 10× PARP Cocktail, 2.5 μL 10× Activated DNA, and 20 μL 1× PARP buffer. The test plate was incubated at 25° C. for 1 hour. The final concentration of the compound was 2 μM to 0.0256 nM, and the DMSO concentration was 1%.
[0240] e) After the incubation, wash the test plate twice with 200 μL of washing solution per well, and then wash twice with 200 μL of PBS per well.
[0241] f) Dilute the Strep-HRP in the kit 500 times with 1x Strep-Diluent solution, add 50 μL per well to the test plate, and incubate at 25° C. for 1 hour.
[0242] g) After the incubation, wash the test plate twice with 200 μL of washing solution per well, and then wash twice with 200 μL of PBS per well.
[0243] PeroxyGlow A and B in the kit were mixed 1:1, 100 μL of the mixture was added to each well of the test plate, and chemiluminescence was immediately read using a PerkinElmer Envision Multilabel Analyzer with an integration time of 0.5 seconds.
[0244] Data analysis: The raw data were converted into inhibition rate, IC using the equation (sample-Min) / (Max-Min)*100%. 50 The value of can be obtained by curve fitting with four parameters (obtained in the "log (inhibitor) vs. response-variable slope" mode in GraphPad Prism). Table 4 provides the inhibitory activity of compound 1 of the present application on PARP1 enzyme.
[0245] Experimental results:
[0246] The PARP-1 enzyme inhibitory activity of the compound 1 of the present application was determined by the above experimental method, and the in vitro enzyme inhibitory activity (IC 50 )See Table 4.
[0247] Test compound number <![CDATA[PARP1(IC 50 ,nM)]]> Compound 1 2.3
[0248] Experimental conclusion: Compound 1 showed excellent inhibitory activity against PARP1.
[0249] Experimental Example 3: MDA-MB-436CTG cell anti-proliferation experiment
[0250] Experimental materials: test compound, RPMI-1640 medium, fetal bovine serum, penicillin / streptomycin antibiotics, MDA-MB-436 cell line, Envision multi-label analyzer (PerkinElmer).
[0251] Experimental steps:
[0252] 1. Experimental methods:
[0253] MDA-MB-436 cells were seeded in a white 96-well plate, with 80 μL of cell suspension per well, containing 3,000 MDA-MB-436 cells. The cell plate was placed in a carbon dioxide incubator for overnight culture.
[0254] The compound to be tested was diluted 5-fold to the 8th concentration, i.e., from 2mM to 26nM, using a dispenser, and a double-well experiment was set up. 78μL of culture medium was added to the middle plate, and then 2μL of the gradient diluted compound per well was transferred to the middle plate according to the corresponding position, and 20μL of each well was transferred to the cell plate after mixing. The cell plate was cultured in a carbon dioxide incubator for 7 days. Prepare another cell plate, and read the signal value on the day of drug addition as the Max value for data analysis. Add 25μL Promega CellTiter-Glo to each well of this cell plate and incubate at room temperature for 10 minutes to stabilize the luminescent signal. Read using PerkinElmer Envision multi-label analyzer.
[0255] 25 μL of Promega CellTiter-Glo reagent was added to each well of the cell plate and incubated at room temperature for 10 minutes to allow the luminescent signal to stabilize. The cells were read using the PerkinElmer Envision Multi-label Analyzer.
[0256] 2. Data analysis: The raw data was converted into inhibition rate, IC using the equation (sample-Min) / (Max-Min)*100%. 50 The value of can be obtained by curve fitting with four parameters (obtained in the "log (inhibitor) vs. response-variable slope" mode in GraphPad Prism). Table 5 provides the inhibitory activity of the compounds of the present application on the proliferation of MDA-MB-436 cells.
[0257] Experimental results: The half inhibitory concentration (IC 50 )See Table 5.
[0258] Table 5 Inhibitory activity of compound 1 and crystal A of compound of formula (I) on proliferation of MDA-MB-436 cells
[0259]
[0260] Experimental conclusion: Compound 1 and crystal A of compound of formula (I) have excellent antiproliferative activity against BRCA1 mutated MDA-MB-436 cells. Among them, crystal A of compound of formula (I) has significant antiproliferative activity against BRCA1 mutated MDA-MB-436 cells.
[0261] Experimental Example 4: MDA-MB-231CTG cell anti-proliferation experiment
[0262] Experimental materials: test compound, R DMEM medium, fetal bovine serum, penicillin / streptomycin antibiotics, MDA-MB-231 cell line, Envision multi-label analyzer.
[0263] Experimental methods:
[0264] MDA-MB-231 cells were seeded in a white 96-well plate, with 80 μL of cell suspension per well, containing 5,000 MDA-MB-231 cells. The cell plate was placed in a carbon dioxide incubator for overnight culture.
[0265] The experiment set 8 concentration points for each compound, and the compound to be tested was diluted 3 times to the 8th concentration, that is, from 2mM to 920nM, using a shotgun, and a double-well experiment was set up. 78μL of culture medium was added to the middle plate, and then 2μL of the gradient diluted compound per well was transferred to the middle plate according to the corresponding position. After mixing, 20μL of each well was transferred to the cell plate. The cell plate was placed in a carbon dioxide incubator and cultured for 3 days. Prepare another cell plate, and read the signal value on the day of drug addition as the Max value for data analysis. Add 25μL Promega CellTiter-Glo to each well of this cell plate and incubate at room temperature for 10 minutes to stabilize the luminescent signal. Reading was performed using a PerkinElmer Envision multi-label analyzer.
[0266] 25 μL of Promega CellTiter-Glo reagent was added to each well of the cell plate and incubated at room temperature for 10 minutes to allow the luminescent signal to stabilize. The cells were read using the PerkinElmer Envision Multi-label Analyzer.
[0267] Data analysis: The raw data were converted into inhibition rate, IC using the equation (sample-Min) / (Max-Min)*100%. 50 The value of can be obtained by curve fitting with four parameters (obtained in the "log (inhibitor) vs. response-variable slope" mode in GraphPad Prism). Table 6 provides the inhibitory activity of the compounds of the present application on the proliferation of MDA-MB-231 cells.
[0268] Experimental results: The antiproliferative activity of compound 1 on BRCA wild-type MDA-MB-231 cells was determined by the above experimental method, and the half inhibitory concentration (IC 50 )See Table 6.
[0269] Compound No. <![CDATA[MDA-MB-231(IC 50 ,μM)]]> Compound 1 >10
[0270] Experimental conclusion: Compound 1 has no inhibitory activity against BRCA wild-type MDA-MB-231 cells, indicating that compound 1 has excellent selectivity.
[0271] Experimental Example 5: PARylation anti-proliferation experiment
[0272] Experimental materials: test compound, F12K culture medium, Lovo cells, Anti-Poly (ADP-ribose) mouse monoclonal antibody; FITC-labeled goat anti-mouse IgG; hydrogen peroxide; DAPI; PBS; methanol; acetone; Tween-20; skim milk powder; Envision multi-label analyzer.
[0273] Reagent configuration:
[0274] Day 1: LOVO cells were plated at 60,000 cells / well and incubated at 37°C with 5% CO 2 ,overnight.
[0275] Day 2: Reagent preparation:
[0276] 1. Washing solution: Add Tween-20 to 1x PBS. The final concentration of Tween-20 is 0.05%.
[0277] 2. Blocking solution: Add skimmed milk powder to the washing solution. The final concentration of skimmed milk powder is 5%.
[0278] 3. Cell fixative: Methanol and acetone are mixed in a ratio of 7:3.
[0279] Preparation of test compounds: Compound intermediate plate 1: dilute the compound with DMSO and PBS to a final concentration of 10 μM to 0.13 nM, DMSO concentration is 1%. Compound intermediate plate 2: dilute the compound with DMSO and PBS containing 50 mM hydrogen peroxide to a final concentration of 10 μM to 0.13 nM, DMSO concentration is 1%.
[0280] Experimental steps:
[0281] 1. Remove the supernatant from the cells and add 40 μL of compound from compound intermediate plate 1 to each well of the cell plate and incubate at 37°C for 30 minutes.
[0282] Compound wells: compound, DMSO 1%;
[0283] Negative control and positive control: add 1% DMSO;
[0284] Blank control: PBS was added to the wells without cells.
[0285] 2. After the incubation, take 40 μL of compound from compound intermediate plate 2 to each well of the cell plate. 2 O 2 The final concentration is 25 mM.
[0286] Compound wells: compound + 25 mM H 2 O 2
[0287] Positive control and negative control: 1% DMSO + 25 mM H 2 O 2
[0288] Blank control: wells without cells, add PBS
[0289] 4. After incubation, wash once with pre-cooled PBS on ice, add 100 μL pre-cooled cell fixative to each well, place at -20℃ for 10 minutes, and then discard the cell fixative.
[0290] After 5 air strokes of the stem cell plate, add 200 μL PBS to each well to wash and discard the PBS.
[0291] 6. Add 100 μL of blocking solution to each well and incubate at 25°C for 30 minutes, then discard the blocking solution.
[0292] 7 Add 25 μL anti-PAR antibody to each well. Anti-PAR antibody is diluted 1:50 in blocking solution and incubated at 25°C for 60 minutes.
[0293] Negative control wells: add 25 μL / well blocking solution
[0294] Blank control wells: add 25 μL / well blocking solution
[0295] 8 After the incubation, wash the cell plate 4 times with 200 μL of washing solution per well, each time for 3 minutes, and discard the washing solution.
[0296] 9 Add 25 μL of blocking solution containing 1:50 dilution of FITC-conjugated goat anti-mouse IgG and 0.5 μg / mL DAPI to each well and incubate at 25°C for 60 minutes.
[0297] 10. After incubation, wash the cell plate 4 times with 200 μL of washing solution per well, each time for 3 minutes.
[0298] 11. After removing the liquid, read the corresponding fluorescence values on Envision: FITC: 480nm, 530nm; DAPI: 360nm, 460nm.
[0299] Data analysis: The raw data were normalized using the equation (FITC-negative control) / (DAPI-blank control), and the normalized data were converted into inhibition rate, IC, using the equation (sample-positive control) / (negative control-positive control)*100%. 50 The value of can be obtained by four-parameter curve fitting (obtained in the "log (inhibitor) vs. response-variable slope" mode in GraphPad Prism). Table 7 provides the inhibitory activity of the compounds of the present application.
[0300] Experimental results: The half inhibitory concentration (IC 50 )See Table 7.
[0301] Test compound number <![CDATA[Parylation(IC 50 ,nM)]]> Compound 1 19
[0302] Experimental conclusion: Compound 1 has significant inhibitory activity on poly ADP ribosylation (PARrylation).
[0303] Experimental Example 6: Study on plasma protein binding rate
[0304] The protein binding rate of the compounds of the present application in human, CD-1 mouse and SD rat plasma was determined. 796 μL of blank plasma from human, CD-1 mouse and SD rat was taken, and 4 μL of the working solution of the test compound (400 μM) or the working solution of warfarin (400 μM) was added to make the final concentration of the test compound and warfarin in the plasma sample 2 μM. The samples were thoroughly mixed. The final concentration of DMSO in the organic phase was 0.5%; 50 μL of the test compound and warfarin plasma samples were transferred to the sample receiving plate (three parallels), and the corresponding volume of blank plasma or buffer was immediately added to make the final volume of each sample well 100 μL, and the volume ratio of plasma: dialysis buffer was 1:1, and then 400 μL of stop solution was added to these samples, and this sample will be used as T0 sample for recovery and stability determination. The T0 sample was stored at 2-8°C and waited for subsequent processing with other dialyzed samples; 150 μL of the test compound and warfarin plasma samples were added to the dosing end of each dialysis well, and 150 μL of blank dialysis buffer was added to the receiving end corresponding to the dialysis well. The dialysis plate was then sealed with a gas permeable membrane and placed in a moist, 5% CO 2Incubator at 37°C, shake at about 100 rpm and incubate for 4-hr. After dialysis, transfer 50 μL of the post-dialysis buffer sample and the post-dialysis plasma sample to a new sample receiving plate. Add the corresponding volume of blank plasma or buffer to the sample so that the final volume of each sample well is 100 μL, and the volume ratio of plasma: dialysis buffer is 1:1. All samples were analyzed by LC / MS / MS after protein precipitation, and the formula: protein unbound rate (%) = 100*drug concentration passing through the dialysis membrane / drug concentration not passing through the dialysate, protein binding rate (%) = 100-% protein unbound rate, % recovery rate = 100*(drug concentration passing through the dialysis membrane + drug concentration not passing through the dialysate) / total drug concentration before dialysis. Calculate protein binding rate and recovery rate.
[0305] Experimental results: see Table 8
[0306] Table 8 Plasma protein binding rate of compound 1 in different species
[0307]
[0308] Experimental conclusion: Compound 1 has an appropriate plasma protein binding rate.
[0309] Experimental Example 7: Cytochrome P450 isozyme inhibition study
[0310] Determine the inhibitory activity of the test compound on different subtypes of human cytochrome P450 isozymes. Prepare the test compound, standard inhibitor (100× final concentration) and mixed substrate working solution; take out the microsomes frozen in the -80°C refrigerator and thaw them. Add 2μL of the test compound and standard inhibitor solution to the corresponding wells, and add 2μL of the corresponding solvent to the inhibitor-free control well (NIC) and blank control well (Blank); secondly, add 20μL of the mixed substrate solution to the corresponding wells, except for the Blank well (add 20μL PB to the Blank well); prepare the human liver microsome solution (mark the date after use and put it back in the refrigerator immediately), and then add 158μL of the human liver microsome solution to all wells; put the above sample plate in a 37°C water bath for pre-incubation, and then prepare the coenzyme factor (NADPH) solution; after 10 minutes, add 20μL NADPH solution was added to all wells, the sample plate was shaken and incubated in a 37°C water bath for 10 minutes; at the corresponding time point, 400 μL of cold acetonitrile solution (internal standards were 200 ng / mL tolbutamide and labetalol) was added to terminate the reaction; after the sample plate was mixed evenly, it was centrifuged at 4,000 rpm for 20 minutes to precipitate the protein; 200 μL of supernatant was added to 100 μL of water, shaken and sent for LC / MS / MS detection.
[0311] Experimental results: See Table 9.
[0312] Conclusion: Compound 1 has no or weak inhibitory effect on the five CYP enzymes.
[0313] Table 9 Results of the experimental inhibition of compound 1 on cytochrome P450 isozymes
[0314]
[0315] Experimental Example 8: Microsomal Metabolic Stability
[0316] Aim: To test the metabolic stability of the test compounds in liver microsomes of three species.
[0317] Experimental method: 1 μM test compound and microsomes (0.5 mg / mL) were incubated at 37°C with NADPH regeneration system; positive controls were testosterone (3A4 substrate), propionate (2D6 substrate) and diclofenac (2C9 substrate), and positive controls and microsomes (0.5 mg / mL) were incubated at 37°C with NADPH regeneration system; samples at different time points (0, 5, 10, 20, 30 and 60 minutes) were directly mixed with cold acetonitrile containing internal standard to terminate the reaction; compounds and microsomes were incubated for 60 minutes without NADPH regeneration system; one parallel was performed for each time point (n=1); samples were analyzed by LC / MS / MS; the concentration of the compound was characterized by the ratio of the peak area of the analyte to the peak area of the internal standard.
[0318] Experimental results: see Table 10
[0319] Table 10 Stability of compound 1 in liver microsomes of different species
[0320]
[0321] Experimental conclusion: Compound 1 has moderate stability in three species: rats, humans and mice.
[0322] Experimental Example 9: Single-dose pharmacokinetic study in mice
[0323] Experimental purpose: Male C57BL / 6 mice were used as test animals. The drug concentrations in plasma, liver and cerebrospinal fluid of the compound were determined after a single administration and the pharmacokinetic behavior was evaluated.
[0324] Experimental method: Healthy adult male C57BL / 6 mice were selected for oral administration. The candidate compound was mixed with an appropriate amount of 10% DMSO / 90% (20% hydroxypropyl-β-cyclodextrin), vortexed and sonicated to prepare a 0.5 mg / mL clear solution for use. After intravenous injection of 1 mg / kg and oral administration of 5 mg / kg to mice, whole blood was collected for a certain period of time to prepare plasma, and liver and cerebrospinal fluid were collected. After sample pretreatment, the drug concentration was analyzed by LC-MS / MS method, and the pharmacokinetic parameters were calculated using Phoenix WinNonlin software.
[0325] Experimental results: See Table 11.
[0326] Experimental conclusion: Compound 1 has good AUC0-last and bioavailability in mice.
[0327] Table 11 Pharmacokinetic experimental results of compound 1 in mice and rats
[0328]
[0329] Experimental Example 10: In vivo pharmacodynamic study of the test compound on a BALB / c nude mouse model of subcutaneous xenograft tumors of human breast cancer MDA-MB-436 cells
[0330] Purpose: To evaluate the in vivo efficacy of the test compounds on subcutaneous xenografts of human breast cancer MDA-MB-436 cells in BALB / c nude mice model.
[0331] Experimental design:
[0332] Table 12 Animal groups and dosing regimens for in vivo efficacy experiments of compound 1
[0333]
[0334] Note: 1. N: number of mice per group; 2. Dosing volume: 10 μl / g based on mouse body weight. If the body weight decreases by more than 15%, the dosing regimen should be adjusted accordingly. 3. QD: once a day; PO: oral administration.
[0335] Experimental materials: Select female BALB / c nude mice of age and weight: 6-8 weeks old, weighing 18-22 grams. The experiment started after the animals were raised in the experimental environment for 3-7 days after arrival. The animal information card for each cage indicated the number of animals in the cage, gender, strain, receipt date, dosing regimen, experimental number, group and start date of the experiment. All cages, bedding and drinking water were sterilized before use. Cages, feed and drinking water were changed twice a week. Experimental animals were identified with ear tags. Test products: Niraparib, compound 1. All test products were prepared using 10% DMSO + 90% (20% HP-β-CD) as the solvent, and the blank control group was only administered with this solvent.
[0336] Experimental methods:
[0337] 1. Cell culture. Human breast cancer MDA-MB-436 cells (ATCC, Manassas, VA, Catalog No.: HTB-130) were cultured in monolayer in vitro in RPMI-1640 medium supplemented with 10% fetal bovine serum, 1% anti-anti, 37°C and 5% CO 2 Culture in an incubator. Perform routine digestion and subculture with trypsin-EDTA twice a week. When the cell saturation is 80%-90% and the number reaches the required level, collect the cells, count them, and inoculate them.
[0338] 2. Tumor cell inoculation (tumor inoculation). 0.2 mL (1×10 7 MDA-MB-436 cells (with Matrigel, volume ratio of 1:1) were subcutaneously inoculated on the right back of each mouse, and the average tumor volume reached 318 mm 3 Randomization and drug administration began at 14:00.
[0339] 3. Daily observation of experimental animals: The health status and mortality of animals are monitored daily. Routine examinations include observing the effects of tumor growth and drug treatment on the daily behavior of animals, such as behavioral activities, food and water intake, weight changes, physical signs or other abnormal conditions.
[0340] 4. Tumor measurement and experimental indicators: The experimental indicators are to examine whether tumor growth is inhibited, delayed or cured. The tumor diameter is measured with a vernier caliper twice a week. The calculation formula for tumor volume is: V = 0.5a × b2, a and b represent the long diameter and short diameter of the tumor, respectively. The anti-tumor efficacy of the compound is evaluated by TGI (%) or relative tumor proliferation rate T / C (%). TGI (%) reflects the tumor growth inhibition rate. Calculation of TGI (%): TGI (%) = [(1-(average tumor volume at the end of administration of a certain treatment group - average tumor volume at the beginning of administration of the treatment group)) / (average tumor volume at the end of treatment of the solvent control group - average tumor volume at the beginning of treatment of the solvent control group)] × 100%. Relative tumor proliferation rate T / C (%): The calculation formula is as follows: T / C% = T RTV / C RTV ×100%(T RTV :RTV in treatment group; C RTV : negative control group RTV). The relative tumor volume (RTV) was calculated based on the results of tumor measurement. The calculation formula was RTV = Vt / V0, where V0 was the average tumor volume measured at the time of group administration (i.e., d0), Vt was the average tumor volume at a certain measurement, and T RTV With C RTV Get data from the same day.
[0341] 5. Statistical analysis: including the mean and standard error (SEM) of the tumor volume at each time point for each group. The treatment group showed the best therapeutic effect on the 27th day after administration at the end of the trial, so statistical analysis was performed based on this data to evaluate the differences between the groups. The experimental data were analyzed using one-way ANOVA and the Games-Howell method. All data were analyzed using SPSS 17.0. p < 0.05 was considered to be significantly different.
[0342] Experimental results:
[0343] 1. The body weight of experimental animals is used as a reference indicator for indirect determination of drug toxicity. In this model, no other morbidity or mortality occurred during the experiment.
[0344] 2. Efficacy evaluation index of the test compound:
[0345] Table 13 Evaluation of the anti-tumor efficacy of the test compound on the subcutaneous xenograft tumor model of human breast cancer MDA-MB-436 cells (calculated based on the tumor volume on the 27th day after administration)
[0346]
[0347]
[0348] Note: a. Mean ± SEM. b. Tumor growth inhibition was calculated by T / C and TGI. The cp value is the significance of the tumor volume of each group compared with the vehicle group on day 27.
[0349] Experimental conclusion: The efficacy of compound 1 showed dose-dependency under a given dosage gradient, and the tumor growth inhibition was excellent. From the perspective of body weight change, the body weight of the three dose groups of compound 1 did not change much, and all showed good tolerability.
[0350] Experimental Example 11: Unit cell parameters of single crystal prepared from crystal A of compound of formula (I)
[0351] Single crystal prepared from the compound of formula (I) crystal A:
[0352] 15 mg of the crystalline A sample of compound (I) was dissolved in 1 mL of ethanol / acetone / water (2:2:1) at room temperature. The sample solution was placed in a 4 mL semi-sealed sample bottle and slowly evaporated at room temperature to obtain yellow block crystals on the third day.
[0353] Experimental results:
[0354] The three-dimensional structure ellipsoid diagram of the single crystal prepared from the crystal A of the compound of formula (I) is shown in Fig.10 , which is R configuration.
[0355] Example 12: Potentiometric titration to determine the chloride ion content in the crystal A of the compound of formula (1)
[0356] Experimental materials: automatic potentiometric titrator, electronic balance, ultrapure water meter, silver nitrate titration solution (0.1 mol / L)
[0357] Test process:
[0358] 1) Take 50 mL of purified water and put it into an appropriate beaker and mark it as Blank;
[0359] 2) Weigh about 100 mg of the compound of formula (I) crystal A, accurately weigh it, put it into an appropriate beaker, add 50 mL of purified water to dissolve it, and mark it as the test solution;
[0360] 3) According to the potentiometric titration method (Chinese Pharmacopoeia Part IV General Rules 0701), the test solution and blank solution were titrated with silver nitrate titrant (0.1 mol / L). Each 1 mL of silver nitrate titrant (0.1 mol / L) is equivalent to 3.545 mg of chlorine (Cl).
[0361] calculate:
[0362]
[0363] Where:
[0364] F: Titer, 1 mL of silver nitrate titration solution (0.1 mol / L) is equivalent to 3.545 mg of chlorine (Cl);
[0365] W SPL : The sample amount of the test solution (g);
[0366] V SPL : The volume of silver nitrate titration solution (0.1 mol / L) consumed by the test solution (mL);
[0367] V 0 : Volume (mL) of silver nitrate titration solution (0.1 mol / L) consumed by blank solution.
[0368] Test results: Calculated by the above formula, the chloride ion content is 8.7%.
[0369] Test conclusion: Based on the chloride ion content, it can be concluded that the compound of formula (I) crystal A contains a hydrochloride salt.
Claims
1. Crystallization of the compound of formula (I): in, The X-ray powder diffraction spectrum of the crystal using Cu Kα radiation comprises 12, 13, 14, 15 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 8.59±0.20°, 11.74±0.20°, 12.34±0.20°, 12.56±0.20°, 13.32±0.20°, 13.88±0.20°, 14.70±0.20°, 15.38±0.20°, 16.00±0.20°, 17.20±0.20°, 18.80±0.20°, 19.40±0.20°, 19.72±0.20°, 20.76±0.20°, 21.30±0.20°, 21.73±0.20°, 22.24±0.20°, 0.20°, 22.56±0.20°, 23.50±0.20°, 24.02±0.20°, 25.14±0.20°, 25.96±0.20°, 26.84±0.20°, 27.48±0.20°, 28.20±0.20°, 29.32±0.20°, 30.36±0.2 0°, 31.68±0.20°, 31.98±0.20°, 32.28±0.20°, 32.90±0.20°, 33.59±0.20°, 34.72±0.20°, 35.22±0.20°, 35.98±0.20°, 36.58±0.20° and 38.48±0.20°.
2. The crystal of the compound of formula (I) according to claim 1, wherein The crystal has the following X-ray powder diffraction spectrum data:
3. The crystal of the compound of formula (I) according to claim 1 or 2, wherein The differential scanning calorimetry curve of the crystal has an onset of an exothermic peak at 285.6±5°C and / or a peak of an exothermic peak at 288.6±5°C.
4. Crystallization of the compound of formula (I): in, The X-ray powder diffraction spectrum of the crystal using Cu Kα radiation comprises 7, 8, 9, 10 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 11.52±0.20°, 13.66±0.20°, 14.28±0.20°, 14.72±0.20°, 15.86±0.20°, 16.84±0.20°, 18.30±0.20°, 18.72±0.20°, 21.62±0.20°, 23.14±0.20°, 23.54±0.20°, 24.48±0.20°, 24.84±0.20°, 26.70±0.20°, 27.91±0.20°, 28.83±0.20°, 29.87±0.20°, 30. 5.80±0.20°, 26.28±0.20°, 27.96±0.20°, 28.40±0.20°, 28.84±0.20°, 29.82±0.20°, 30.22±0.20°, 31.74±0.20°, 32.04±0.20°, 32.69±0.20°, 33.90±0.20°, 34.50±0.20°, 35.02±0.20°, 36.08±0.20°, 36.94±0.20°, 37.46±0.20° and 37.92±0.20°.
5. The crystal of the compound of formula (I) according to claim 4, wherein The crystal has the following X-ray powder diffraction spectrum data:
6. The crystal of the compound of formula (I) according to claim 4 or 5, wherein The differential scanning calorimetry curve of the crystal has a starting point of an exothermic peak at 287.4±5°C and / or a peak of an exothermic peak at 290.6±5°C.
7. Crystallization of the compound of formula (I): in, The X-ray powder diffraction spectrum of the crystal using Cu Kα radiation comprises 12, 13, 14, 15 or more characteristic peaks selected from the following diffraction peaks at 2θ angles: 6.46±0.20°, 9.59±0.20°, 9.94±0.20°, 10.58±0.20°, 11.42±0.20°, 12.44±0.20°, 13.40±0.20°, 14.86±0.20°, 15.66±0.20°, 16.32±0.20°, 17.00±0.20°, 17.54±0.20°, 17.84±0.20°, 18.78±0.20°, 19.82±0.20°, .20°, 20.22±0.20°, 20.68±0.20°, 20.98±0.20°, 21.70±0.20°, 22.32±0.20°, 22.68±0.20°, 23.30±0.20°, 24.08±0.20°, 24.92±0.20°, 26.14±0.20°, 26.86±0.20°, 27.34±0.20°, 27.82±0.20°, 28.52±0.20°, 29.34±0.20°, 30.18±0.20°, 31.36±0.20° and 32.36±0.20°.
8. The crystal of the compound of formula (I) according to claim 7, wherein The crystal has the following X-ray powder diffraction spectrum data:
9. The crystal of the compound of formula (I) according to claim 7 or 8, wherein The differential scanning calorimetry curve of the crystal has a starting point of an exothermic peak at 261.6±5°C and / or a peak of an exothermic peak at 267.5±5°C.
10. A crystalline composition of a compound of formula (I), wherein the crystals of the compound of formula (I) according to any one of claims 1 to 9 account for more than 50% by weight of the crystalline composition.
11. The crystalline composition according to claim 10, wherein the crystals of the compound of formula (I) according to any one of claims 1 to 9 account for more than 75% by weight of the crystalline composition.
12. The crystalline composition according to claim 11, wherein the crystals of the compound of formula (I) according to any one of claims 1 to 9 account for more than 90% by weight of the crystalline composition.
13. The crystalline composition according to claim 12, wherein the crystals of the compound of formula (I) according to any one of claims 1 to 9 account for more than 95% by weight of the crystalline composition.
14. A pharmaceutical composition comprising a therapeutically effective amount of a crystal of a compound of formula (I) according to any one of claims 1 to 9 and a crystalline composition according to any one of claims 10 to 13, wherein the pharmaceutical composition comprises at least one pharmaceutically acceptable carrier or other excipient.
15. Use of a crystal of a compound of formula (I) according to any one of claims 1 to 9, a crystalline composition according to any one of claims 10 to 13, and a pharmaceutical composition according to claim 14 in the preparation of a medicament for preventing or treating a PARP receptor-related disorder, wherein the PARP receptor-related disorder is selected from a tumor or a cancer.
16. The use according to claim 15, wherein the PARP receptor-related disease is breast cancer.
17. A method for preparing a crystal of a compound of formula (I) according to claim 1 or 2, wherein: The preparation method of the crystal is as follows: the amorphous material of the compound of formula (I) is heated and stirred in an organic solvent, further cooled to crystallize, and filtered to obtain the crystal; the amorphous material of the compound of formula (I) has an X-ray powder diffraction spectrum using Cu Kα radiation as shown in FIG1 ; in the preparation method of the crystal, the organic solvent is selected from acetone, tetrahydrofuran and ethyl acetate.
18. The method for preparing the crystal of the compound of formula (I) according to claim 17, wherein the organic solvent is selected from acetone.
19. The method for preparing a crystal according to claim 18, wherein the volume: molar ratio of the organic solvent to the amorphous substance of the compound of formula (I) is 2-10 mL: 1 mmol.
20. The method for preparing a crystal according to claim 19, wherein the volume: molar ratio of the organic solvent to the amorphous substance of the compound of formula (I) is 4-6 mL: 1 mmol.
21. The method for preparing a crystal according to claim 18, wherein the amorphous compound of formula (I) is obtained by stirring compound 1 in the presence of an organic solvent and hydrochloric acid, crystallizing, and filtering; the organic solvent is selected from ethyl acetate; and the compound 1 has the following structure:
Citation Information
Patent Citations
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
CN102869258A
Tricyclic inhibitors of poly(ADP-ribose) polymerases
CN1342161A
